Gliflozinas. Inhibidores del cotransporte sodio-glucosa Tipo 2 // Ezequiel J Zaidel Figura 4 A y B Porcentaje de la población adulta que potencialmente debería recibir gliflozinas según las guías vigentes. DM2: Diabetes tipo 2; ICC: insuficiencia cardiaca crónica; IRC: insuficiencia renal crónica 43
Gliflozinas. Inhibidores del cotransporte sodio-glucosa Tipo 2 // Ezequiel J Zaidel Bibliografía sugerida 1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925. 2. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389. 3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720. 4. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-2215. doi:10.1161/CIRCULATIONAHA.120.050255 5. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-139. doi:10.1056/NEJMoa2030186. 6. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network metaanalysis of randomised controlled trials [published correction appears in BMJ. 2022 Jan 18;376:o109]. BMJ. 2021;372:m4573. Published 2021 Jan 13. doi:10.1136/bmj.m4573. 7. Zaidel EJ, Rodriguez Rohwain V, Serra HA et al. Efficacy of sodium glucose cotransporter 2 inhibitors in reducing heart failure hospitalizations. systematic review and metanalysis. Eur J Heart Fail 2020. https://doi. org/10.1002/ejhf.1963. 8. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034. 9. Guías NICE: https://www.nice.org.uk/guidance/ng28/. 44
